Terns Pharmaceuticals (TERN) Stock Forecast, Price Target & Predictions
TERN Stock Forecast
Terns Pharmaceuticals stock forecast is as follows: an average price target of $14.25 (represents a 154.46% upside from TERN’s last price of $5.60) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
TERN Price Target
The average price target for Terns Pharmaceuticals (TERN) is $14.25 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $7.00. This represents a potential 154.46% upside from TERN's last price of $5.60.
TERN Analyst Ratings
According to 8 Wall Street analysts, Terns Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for TERN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Terns Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Etzer Darout | BMO Capital | $26.00 | $8.96 | 190.34% | 364.29% |
| Aug 21, 2024 | Graig Suvannavejh | Mizuho Securities | $10.00 | $7.79 | 28.37% | 78.57% |
| Mar 15, 2024 | Etzer Darout | BMO Capital | $19.00 | $7.20 | 163.89% | 239.29% |
| Dec 29, 2022 | - | H.C. Wainwright | $7.00 | $9.60 | -27.08% | 25.00% |
| Dec 20, 2022 | - | Goldman Sachs | $14.00 | $7.78 | 79.95% | 150.00% |
| Sep 27, 2022 | Corinne Jenkins | Goldman Sachs | $9.00 | $4.92 | 82.93% | 60.71% |
The latest Terns Pharmaceuticals stock forecast, released on Sep 16, 2024 by Etzer Darout from BMO Capital, set a price target of $26.00, which represents a 190.34% increase from the stock price at the time of the forecast ($8.96), and a 364.29% increase from TERN last price ($5.60).
Terns Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $18.00 | $18.33 |
| Last Closing Price | $5.60 | $5.60 | $5.60 |
| Upside/Downside | -100.00% | 221.43% | 227.32% |
In the current month, the average price target of Terns Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Terns Pharmaceuticals's last price of $5.60. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 10, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 10, 2024 | Deutsche Bank | - | Buy | Upgrade |
| Sep 10, 2024 | Loop Capital Markets | Buy | Buy | Hold |
| Sep 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Aug 10, 2023 | Needham | Neutral | Neutral | Hold |
| Jun 28, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Feb 07, 2023 | UBS | - | Buy | Initialise |
| Dec 29, 2022 | Citigroup | Neutral | Neutral | Hold |
| Dec 20, 2022 | Goldman Sachs | Buy | Buy | Hold |
Terns Pharmaceuticals's last stock rating was published by JMP Securities on Sep 10, 2024. The company gave TERN a "Market Outperform" rating, the same as its previous rate.
Terns Pharmaceuticals Financial Forecast
Terns Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $2.92M | - | - |
| High Forecast | - | - | - | - | $2.92M | - | - |
| Low Forecast | - | - | - | - | $2.92M | - | - |
| # Analysts | - | - | - | - | 6 | - | - |
| Surprise % | - | - | - | - | - | - | - |
Terns Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TERN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Terns Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $1.75M | - | - |
| High Forecast | - | - | - | - | $1.75M | - | - |
| Low Forecast | - | - | - | - | $1.75M | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict TERN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Terns Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Terns Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-28.78M | $-27.09M | $-26.44M | $-25.79M | $-24.07M | $-24.94M | $-25.25M |
| High Forecast | $-28.78M | $-27.09M | $-26.44M | $-24.01M | $-20.86M | $-24.94M | $-25.25M |
| Low Forecast | $-28.78M | $-27.09M | $-26.44M | $-26.68M | $-30.48M | $-24.94M | $-25.25M |
| Surprise % | - | - | - | - | - | - | - |
Terns Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TERN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Terns Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $13.78M | - | - |
| High Forecast | - | - | - | - | $13.78M | - | - |
| Low Forecast | - | - | - | - | $13.78M | - | - |
| Surprise % | - | - | - | - | - | - | - |
Terns Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TERN last annual SG&A of $NaN (undefined).
Terns Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 6 | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.37 | $-0.35 | $-0.34 | $-0.33 | $-0.31 | $-0.32 | $-0.34 |
| High Forecast | $-0.37 | $-0.35 | $-0.34 | $-0.31 | $-0.27 | $-0.32 | $-0.34 |
| Low Forecast | $-0.37 | $-0.35 | $-0.34 | $-0.34 | $-0.39 | $-0.32 | $-0.34 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Terns Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TERN previous annual EPS of $NaN (undefined).
Terns Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
| INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
| PDSB | PDS Bio | $2.03 | $9.00 | 343.35% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.37 | $7.00 | 195.36% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
| MREO | Mereo BioPharma Group | $3.58 | $6.75 | 88.55% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.23 | $6.67 | 27.53% | Buy |
| HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |